Original researchAn open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
References (22)
- et al.
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
Am J Cardiol
(2001) - et al.
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
Am J Cardiol
(2002) - et al.
Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
Atherosclerosis
(2000) - et al.
Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C
Atheroscler Suppl
(2001) - et al.
Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection
J Chromatogr B Analyt Technol Biomed Life Sci
(2002) - et al.
Optimizing the pharmacology of statins: Characteristics of rosuvastatin
Atheroscler Suppl
(2002) - et al.
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study
- et al.
Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin
Drug Metab Dispos
(2002) - et al.
No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor
J Clin Pharmacol
(2002) - et al.
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Br J Clin Pharmacol
(2003)
The effect of fluconazole on the pharmacokinetics of rosuvastatin
Eur J Clin Pharmacol
(2002)
Cited by (0)
Copyright © 2003 Published by Elsevier Inc.